Scroll Down

  • Home

  • >
  • Neurodegenerative

  • >
  • Heuron AgingCare Suite™

  • >
  • Heuron IPD

Heuron IPD

Assists in the diagnosis of Parkinson’s disease by analyzing and quantifying on brain MRI. MFDS Approved CE Marked Singapore
Compliant
Taiwan FDA
Approved

Heuron IPD Brochure

  • MRI Analysis

  • Assessment in the
    asymptomatic stage

  • High Sensitivity
    and Specificity

Workflow Improvement

Detects early signs of Parkinson's disease through the analysis of dopaminergic neuron damage in the nigrosome area on brain MRI. Differentiates Parkinson’s from other movement disorders that do not exhibit the loss of dopaminergic neurons.

Supported Features

Detects and visualizes the nigrosome area on Susceptibility Map-Weighted Imaging (SMWI) to analyze the presence or absence of degeneration of dopaminergic neurons.

High Diagnostic Performance

Provides essential support for the rapid and
accurate quantification of nigral
hyperintensity, assisting in the diagnosis of
idiopathic Parkinson's disease and the
prediction of symptom severity.

*Source:
Suh PS et al., Deep learning-based algorithm for automatic quantification of nigrosome-1 and Parkinsonism classification using susceptibilitymap-weighted MRI. Am J Neuroradiol. 2024.

Heuron IPD

Parkinson’s Disease Dignostic-Aid

Explore the product's features firsthand by clicking directly on your screen.

L
R

1 / 8

Discover more with our demo.

TOP